Bethesda, MD, USA
With the number of collaborations between industry, regulatory agencies, academia and patient groups on the rise, there is growing interest in the role that public-private partnerships (PPPs) play in delivering innovative tools and methodologies for medical product development.
This 2nd annual public conference co-sponsored by the Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path) will feature cross-sector participants discussing challenges and opportunities in the rapidly-evolving PPP space. The objective is to identify mechanisms for assessing the productivity of PPPs, enhancing effectiveness of PPPs, coordinating individual PPP efforts to avoid duplication, and adopting best practices on data sharing and other cross-cutting issues in order to streamline medical product development world-wide.
The opening session will discuss how to measure the output of partnerships set up to advance regulatory science and leverage global biopharmaceutical development. The second session will review how two well-established PPPs working on safety biomarkers (PSTC & SAFE-T), have collaborated to deliver results. The final session of the day will focus on maximizing the value of data shared by multiple organizations, from best methods to success stories and more.
|Session 1: Partnerships to Advance Regulatory Science and Leverage Global Biopharmaceutical Development|
Co-chairs: Martha Brumfield and Michel Goldman
|Session 2: Safety Biomarkers: PSTC and SAFE-T Collaboration|
Co-Chairs: John-Michael Sauer and Michael Merz
|Session 3: Maximizing the value of data shared by multiple organizations|
Co-Chairs: Enrique Avilés and Ann Martin